Form 4 for RCUS Arcus Biosciences, Inc.
Accepted 2025-01-03 00:00:00 ET · period of report 2024-12-31 · accession 0001724521-25-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-01-03 | 2024-12-31 | RCUS | Goeltz II Robert C. | CFO | S - Sale | $15.00 | -3,594 | 60.1K | -6% | -$53.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-12-31 | S | D | 3,594 | $15.00 | 60,138 | D | — | — | (F1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2023. |